Norverapamil (hydrochloride)

Norverapamil hydrochloride ((±) -Norverapamil hydrochloride), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].

Product Specifications

CAS Number

[67812-42-4]

Product Name Alternative

(±) -Norverapamil (hydrochloride) ; D591 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Calcium Channel; Drug Metabolite; P-glycoprotein

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Norverapamil-hydrochloride.html

Purity

99.80

Solubility

DMSO : ≥ 31 mg/mL|H2O : ≥ 50 mg/mL

Smiles

N#CC(C(C)C)(CCCNCCC1=CC=C(OC)C(OC)=C1)C2=CC=C(OC)C(OC)=C2.[H]Cl

Molecular Formula

C26H37ClN2O4

Molecular Weight

477.04

Precautions

H302, H315, H319, H335

References & Citations

[1]Adams KN, et al. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J Infect Dis. 2014 Aug 1;210 (3) :456-66.|[2]Wang J et al. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Eur J Pharm Sci. 2013 Nov 20;50 (3-4) :290-302.|[3]Choi DH, et al. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet. 2009 Jul-Sep;34 (3-4) :163-8.|[4]Pauli-Magnus C, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293 (2) :376-82.